振东制药(300158) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥754,532,591.77, a decrease of 3.53% compared to ¥782,130,269.05 in the same period last year[4] - Net profit attributable to shareholders was ¥1,157,176.86, down 94.99% from ¥23,101,557.95 year-on-year[4] - Total revenue for the current period was ¥754,532,591.77, a decrease of 3.6% from ¥782,130,269.05 in the previous period[22] - Operating profit for the current period was ¥12,495,546.65, down 61.3% from ¥32,289,666.48 in the previous period[22] - Net profit for the current period is ¥1,005,768.43, down from ¥22,347,124.36 in the previous period, representing a decrease of about 95.5%[23] - Basic and diluted earnings per share decreased from 0.0225 to 0.0012, a drop of approximately 94.7%[23] Cash Flow - The net cash flow from operating activities was -¥330,009,937.17, a significant decline of 1,282.28% compared to -¥23,874,405.33 in the previous year[11] - Operating cash flow for the current period is -330,009,937.17, compared to -23,874,405.33 in the previous period, reflecting a worsening cash flow situation[25] - Investment cash flow for the current period is ¥259,074,434.79, a significant improvement from -¥43,843,437.71 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,634,578,812.78, a decrease of 6.99% from ¥4,982,724,545.73 at the end of the previous year[4] - Total current assets decreased to ¥2,858,122,396.26 from ¥3,215,616,760.00, a reduction of 11.2%[20] - Total liabilities decreased to ¥1,010,858,921.83 from ¥1,322,468,279.14, a decline of 23.5%[21] - The company reported a net loss in retained earnings of ¥1,386,996,474.81, slightly improved from a loss of ¥1,388,153,651.67 in the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 48,584[13] - The company has a total of 302,230,191 CNY ordinary shares held by Shanxi Zhendong Health Industry Group Co., Ltd., which is the controlling shareholder[14] - The third phase employee stock ownership plan holds 38,967,619 CNY ordinary shares, representing a significant portion of the company's equity structure[14] - The company has a total of 6,000,000 CNY ordinary shares held by Hu Wenqin, representing 0.60% of the total shares[14] - Liu Zhenwei holds 5,698,100 CNY ordinary shares, accounting for 0.57% of the total shares[14] - The company has a total of 10,054,000 CNY shares held in a repurchase special securities account, representing 1.00% of the total shares[14] - The company has a total of 41,207,635 CNY shares held by the asset management plan supporting the development of private enterprises[14] - The company has a total of 5,644,300 CNY shares held by Liu Yubin, representing 0.56% of the total shares[14] - The company has a total of 2,728,900 CNY shares held by Zhou Jie, accounting for 0.27% of the total shares[14] Operating Costs and Expenses - Total operating costs decreased to ¥759,035,483.80 from ¥795,147,632.83, reflecting a reduction of 4.5%[22] - The company incurred operating expenses of ¥932,894,187.96, which is an increase compared to ¥841,787,893.34 in the previous period[25] - Research and development expenses increased to ¥48,435,492.50 from ¥38,447,733.67, reflecting a growth of 26.0%[22] Other Financial Metrics - The company reported a basic earnings per share of ¥0.0012, down 94.67% from ¥0.0225 in the same period last year[4] - Investment income for Q1 2025 was ¥3,416,186.80, a decrease of 79.77% compared to the previous year[10] - The company reported a decrease in sales revenue from ¥800,525,339.92 to ¥597,926,743.45, a decline of about 25.3%[25] - Other comprehensive income attributable to the parent company is 652.32, a recovery from -4.44 in the previous period[23] Audit Information - The company has not undergone an audit for the first quarter report[27]